Deutsche Bank AG Has $407.40 Million Holdings in Stryker Corporation $SYK

Deutsche Bank AG raised its position in shares of Stryker Corporation (NYSE:SYK) by 3.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,159,117 shares of the medical technology company’s stock after purchasing an additional 43,382 shares during the quarter. Deutsche Bank AG’s holdings in Stryker were worth $407,395,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Godfrey Financial Associates Inc. acquired a new stake in Stryker during the 4th quarter valued at approximately $26,000. United Financial Planning Group LLC acquired a new position in shares of Stryker in the 3rd quarter valued at about $27,000. Strive Asset Management LLC acquired a new position in shares of Stryker in the 3rd quarter valued at about $30,000. CGC Financial Services LLC acquired a new position in shares of Stryker in the 4th quarter valued at about $29,000. Finally, ANTIPODES PARTNERS Ltd acquired a new position in shares of Stryker in the 3rd quarter valued at about $34,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on SYK shares. Evercore set a $355.00 price objective on Stryker in a research note on Friday, May 1st. Canaccord Genuity Group dropped their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Needham & Company LLC dropped their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a report on Friday, May 1st. Finally, Robert W. Baird set a $385.00 price target on shares of Stryker in a report on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $395.33.

Stryker Price Performance

Shares of NYSE:SYK opened at $308.50 on Thursday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87. The stock’s 50 day moving average is $317.20 and its 200-day moving average is $344.64. The firm has a market capitalization of $118.27 billion, a price-to-earnings ratio of 35.71, a PEG ratio of 1.98 and a beta of 0.78.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same period in the previous year, the company earned $2.84 earnings per share. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Insider Transactions at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 323,264 shares of company stock valued at $100,659,489 over the last ninety days. 4.60% of the stock is owned by company insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.